Effects of nintedanib on the microvascular architecture in a lung fibrosis model

Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis, has anti-fibrotic, anti-inflammatory, and anti-angiogenic activity. We explored the impact of nintedanib on microvascular architecture in a pulmonary fibrosis model. Lung fibrosis was induced in C57B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Angiogenesis
Autors principals: Ackermann, Maximilian, Kim, Yong Ook, Wagner, Willi L., Schuppan, Detlef, Valenzuela, Cristian D., Mentzer, Steven J., Kreuz, Sebastian, Stiller, Detlef, Wollin, Lutz, Konerding, Moritz A.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412751/
https://ncbi.nlm.nih.gov/pubmed/28283856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-017-9543-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars